It can often be difficult for investors to predict the next industry that will boom within the next decade.
What’s not difficult to predict is how current health crises will look within ten years—and how new treatments are certain to have a critical place in the healthcare landscape. That’s why the cutting-edge osteoarthritis treatment by Cytonics is worth investing in today: this global $180B industry is expected to affect 25 percent of American adults by 2030.
Osteoarthritis, which is the most common form of arthritis, is the degradation of the cartilage in joints and underlying bone. Joint cartilage wears down with age, causing severe discomfort when moving knees, elbows, fingers and various joints throughout the body. This condition currently plagues 27 million American adults, making it a significant healthcare issue in the years to come. That’s what makes Cytonics critical in the healthcare industry: its mission to develop first-in-class therapies for treating osteoarthritis will be a life-changing force for millions of American adults.
Proteases are the enzymes at play with osteoarthritis, breaking down the cartilage and causing pain and inflammation with joint movement. Cytonics utilizes the proprietary CYT-108 molecule, an A2M variant that is based on a naturally occurring molecule within the human body. Cytonic’s preliminary preclinical research suggests that CYT-108 has the potential to reverse the progression of cartilage damage in arthritic joints and could restore damage caused by osteoarthritis by 60 percent. That’s because CYT-108 bonds with the protease enzymes, triggering encapsulation by the body’s immune cells. Because CYT-108 bonds with the proteases, this incredible molecule is able to rescue the cartilage from these destructive enzymes.
Over 6,000 patients have been treated using Cytonics’ revolutionary osteoarthritis treatment: it’s only the beginning for this patented arthritic treatment. Unlike previous arthritic treatments, Cytonics doesn’t treat the symptoms: its novel treatment attacks arthritis at the molecular level, reversing cartilage degradation before it can occur.
Cytonics is proven to work, and it solves an issue that harms millions of Americans, making this the perfect time to invest in this opportunity. When it comes to investing, predicting the future is never easy—but arthritis is here to stay, and Cytonics is now here to fight it. Now is the time to jump on this innovative new technology–invest in Cytonics while you still can.
Cytonics is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: https://www.seedinvest.com/cytonics/series.c
When you buy something through a link in this article or from our shop, Big Think earns a small commission. Thank you for supporting our team’s work.